Answers are grounded in this paper and cite their sources.
Background The optimal timing of direct endoscopic necrosectomy (DEN) for walled-off pancreatic necrosis (WON) remains uncertain. We conducted a systematic review and meta-analysis with Trial Sequential Analysis (TSA) to compare the efficacy and safety of immediate vs. step-up DEN in patients with symptomatic WON. Methods PubMed, Web of Science, Scopus and the Cochrane Library were searched through 17 October 2026, with supplementary registry searches. Randomized controlled trials (RCTs) formed the primary analysis, comparative cohorts were analyzed separately. Random-effects models used restricted maximum likelihood and Hartung–Knapp inference. The primary outcome was the total number of DEN sessions under each treatment strategy. TSA and Grading of Recommendations Assessment, Development and Evaluation (GRADE) were applied to RCT evidence. Results Eight studies were included: five RCTs (269 patients) and three cohorts (401 patients). In RCTs, no significant difference in DEN sessions was observed (mean difference [MD] 1.41, 95% CI −0.93 to 3.75; P = 0.169; I 2 = 76.4%). Excluding Saito et al. reduced heterogeneity to 0% and favored step-up treatment (MD 0.95, 95% CI 0.46 to 1.44; P = 0.008). Immediate DEN was associated with less additional percutaneous drainage (risk ratio [RR] 0.55, 95% CI 0.31 to 0.99; P = 0.048), without a significant reduction in surgery (RR 0.44, 95% CI 0.12 to 1.60; P = 0.136). No significant differences were observed in mortality, clinical success, hospital stay or adverse events. Although TSA crossed the efficacy boundary favoring step-up treatment, certainty for DEN sessions remained low because of inconsistency and imprecision in the primary analysis. Conclusions Current RCT evidence does not establish superiority or equivalence of immediate and step-up DEN. DEN-session estimates are heterogeneous and sensitive to study inclusion and inference method. Immediate DEN may reduce additional percutaneous drainage, but this potential benefit requires confirmation. Systematic Review Registration PROSPERO CRD420261334818.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: